osteoarthritis of the knee
Conditions
Interventions
CS Celecoxib combined with sham TENS group:Starting from the first day after surgery, 100mg per dose, twice a day, for 3 weeks postoperatively.
Starting from the first day after surgery, sham electric
CS Celecoxib combined with TENS group:Starting from the first day after surgery, 100mg per dose, twice a day, for 3 weeks postoperatively.
Starting from the first day after surgery, electrical stimula
NCS Celecoxib combined with sham TENS group:Starting from the first day after surgery, 100mg per dose, twice a day, for 3 weeks postoperatively.
Starting from the first day after surgery, sham electri
NCS Celecoxib combined with TENS group:Starting from the first day after surgery, 100mg per dose, twice a day, for 3 weeks postoperatively.
Starting from the first day after surgery, electrical stimul
Sponsors
Honghui Hospital, Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.The study is a randomized controlled trial; 2.Meeting surgical indications, with a diagnosis of knee osteoarthritis confirmed by clinical and imaging examinations; 3.Participants are adult patients scheduled for primary total knee arthroplasty (TKA), aged 50–80 years; 4.American Society of Anesthesiologists (ASA) physical status classification is 1–3; 5.No contraindications to medication; 6.Patients agree to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Abnormal skin at the treatment site; 2.History of allergy to celecoxib; 3.Chronic use of opioid medications including tramadol (daily use for 4 consecutive weeks, with administration within 2 weeks before surgery); 4.Patients with a history of liver or kidney dysfunction, severe cardiopulmonary diseases, severe gastrointestinal diseases, or mental illnesses; 5.Ipsilateral lower extremity neuromuscular deficits; 6.History of opioid abuse or dependence; 7.History of hemorrhagic diseases; 8.Anticoagulant status and/or anticoagulant therapy; 9.Concurrent use of another electrical stimulator (e.g., cardiac pacemaker); 10.Inability to contact researchers during the treatment period; 11.Patients with a history of previous open surgery on the ipsilateral knee joint.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analogue Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Western Ontario and McMaster Universities Osteoarthritis Index;Consumption of opioids;Range of Motion; | — |
Countries
China
Contacts
Public ContactXuchao
Honghui Hospital, Xi'an Jiaotong University
Outcome results
None listed